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Analysis of clinical outcomes according to original
treatment groups 16 years after the pivotal
IFNB-1b trial
G C Ebers,1 A Traboulsee,2 D Li,2 D Langdon,3 A T Reder,4 D S Goodin,5 T Bogumil,6
K Beckmann,7 C Wolf,7 A Konieczny,7 for the Investigators of the 16-year Long-Term
Follow-Up Study
ABSTRACT
Background Evidence for efficacy of disease-modifying
drugs in multiple sclerosis (MS) comes from trials of
short duration. We report results from a 16 y,
retrospective follow-up of the pivotal interferon b-1b
(IFNB-1b) study.
Methods The 372 trial patients were randomly assigned
to placebo (n¼123), IFNB-1b 50 mg (n¼125) or IFNB-1b
250 mg (n¼124) subcutaneously every other day for at
least 2 y. Some remained randomised for up to 5 y but,
subsequently, patients received treatment according to
physicians’ discretion. Patients were re-contacted and
asked to participate. Efficacy related measures included
MRI parameters, relapse rate, the Expanded Disability
Status Scale, the Multiple Sclerosis Functional
Composite Measure and conversion to secondary
progressive MS.
Results Of the 88.2% (328/372) of patients who were
identified, 69.9% (260/372) had available case report
forms. No differences in outcome between original
randomisation groups could be discerned using standard
disability and MRI measures. However, mortality rates
among patients originally treated with IFNB-1b were
lower than in the original placebo group (18.3% (20/109)
for placebo versus 8.3% (9/108) for IFNB-1b 50 mg and
5.4% (6/111) for IFNB-1b 250 mg).
Conclusions The original treatment assignment could
not be shown to influence standard assessments of long-
term efficacy. On-study behaviour of patients was
influenced by factors that could not be controlled with
the sacrifice of randomisation and blinding. Mortality was
higher in patients originally assigned to placebo than
those who had received IFNB-1b 50 mg or 250 mg. The
dataset provides important resources to explore early
predictors of long-term outcome.
INTRODUCTION
Patients with multiple sclerosis (MS) commonly
live 30 or 40 y after disease onset.1 Long-term
outcomes determine the key social, medical and
economic impact of the disease. However, it is not
possible to quantitate or adequately assess the
overall effect of disease-modifying drugs (DMDs)
on disease course. Obstacles include the impossi-
bility of maintaining blinding and randomisation
and the problems in assessing patients who
discontinue treatment.
Pivotal trials have shown beneﬁts from DMDs in
patients with clinically isolated syndromes at risk
of developing MS2e4 and with relapsing-remitting
multiple sclerosis (RRMS).5e14 However, these
trials have been of relatively short duration and the
long-term treatment beneﬁt is less clear.
Interferon b-1b (Betaferon/Betaseron; IFNB-1b)
was approved for treating patients with RRMS
following a pivotal study.5 In this study, treatment
with IFNB-1b 250 mg for 2 y reduced the clinical
relapse rate by 34% compared to placebo
(p¼0.0001). Final analysis at 5 y demonstrated that
the clinical relapse rates each year were one-third
lower in patients treated with IFNB-1b 250 mg than
in placebo-treated patients.6 It was feasible for
patients to defer treatment for 5 y or more allowing
for the inclusion of a group randomised to placebo
at the time of this study. Following completion of
the pivotal trial, patients were under regular
medical care and, thus, free to receive IFNB-1b
250 mg or other treatment as they became available
over time, such as IFNB-1a intramuscularly (im),
glatiramer acetate (GA), mitoxantrone, IFNB-1a
subcutaneously (sc) , in the case of one patient,
natalizumab. MS treatments were chosen by
treating physicians according to conviction making
interpretation of long-term outcomes more
difﬁcult.
In a concurrent analysis of 16 y follow-up data
from the pivotal study of IFNB-1b, no important
safety concerns were identiﬁed in those originally
receiving active treatment. Other studies have also
looked at long-term outcomes associated with
DMD treatment but the observation periods have
been shorter.4 15e20 The purpose of this current
analysis was to explore whether differences in
clinical outcome can be detected at 16 y follow-up
between the originally randomised groups or
patient subgroups from the pivotal IFNB-1b trial,
subsequent use of other treatments or discontinu-
ation of treatment notwithstanding.
METHODS
Patients and study design
The design for this study and the basic methods are
described in detail elsewhere.21 The original pivotal
IFNB-1b study was conducted in 11 clinical centres
in the United States and Canada.5 6 22 Patients who
participated in the original trial (n¼372) were
re-contacted by their original clinical study centre
between January 2005 and October 2005 and were
asked to participate in this 16 y follow-up study
(ClinicalTrials.gov Identiﬁer: NCT00206635).21
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Those who agreed to participate were assessed during 1 day or for
up to 3 days, if necessary. If, for health or personal reasons,
patients chose not to participate in person, they could provide
limited information via a telephone interview. Ethics approval for
the follow-up study was obtained from the institutional review
boards or independent ethical committees of the participating
centres. All patients gave written informed consent.
Treatment
During the original study patients were randomly assigned to
receive placebo (n¼123), IFNB-1b 50 mg (n¼125) or IFNB-1b
250 mg (n¼124) sc every other day for 104 weeks.5 22 Patients
were asked to continue for a further 12 months’ extension phase
of double-blind treatment and evaluations, with some remaining
on the study for up to 5 y. Once IFNB-1b 250 mg was approved
in October 1993, all remaining patients were offered the
commercially available product (Betaferon/Betaseron).
No speciﬁc therapeutic regime was adhered to as part of the
follow-up study. Many patients were on DMDs other than
IFNB-1b during the course of the study. Information on the
treatment history of individuals was collected systematically,
although it was not always possible to determine the precise
duration of treatment for some DMDs because of uncertainty
about the start and stop dates of treatments prescribed. In these
cases, the most conservative estimate of exposure was assumed
using the earliest and latest dates that patients could be
conﬁrmed to be on treatment.
Primary observations
A large number of outcomes were assessed and recorded in this
descriptive and hypothesis-generating study. Deaths and medi-
cation history were gathered. Efﬁcacy and effectiveness related
measures included the level of disability/function as determined
by the Expanded Disability Status Scale (EDSS)23 and the
Multiple Sclerosis Functional Composite Measure (MSFC).24
Conversion to secondary progressive MS (SPMS) and its timing
were based on investigator opinion, and from observation and
review of patient case report forms for worsening disability for
at least 6 months not relapse-attributable. Time to EDSS level
6.0 (intermittent or unilateral ambulation assistance required)
and relapse rates were obtained from retrospective data review.
Careful assessment of baseline characteristics is extensively
described elsewhere.21 Other outcomes included MRI measures
and assessments of cognitive function, and will also be reported
elsewhere.
Subgroup analysis
The long-term follow-up (LT) patient population, nearly all of
whom had received IFNB-1b at some time during the past 16 y,
was then divided into three predeﬁned groups according to
duration of exposure to IFNB-1b 250 mg. These groups were
arbitrarily deﬁned as (1) IFNB-1b 250 mg for <10% of the time,
(2) IFNB-1b 250 mg for 10e79% of the time or (3) IFNB-1b
250 mg for $80% of the time. These divisions were intended to
identify the group that had received high-dose IFNB-1b
continuously from the beginning of the trial ($80%), another
that had not received IFNB-1b 250 mg during the pivotal trial
and had very limited exposure to IFNB-1b 250 mg thereafter
(IFNB-1b 250 mg treatment for <10% of the time) and a third
group comprising all other individuals. Comparison of these
three groups was planned to analyse the relation between IFNB-
1b use and progression-related outcomes.
Composite outcome
Heterogeneity is a key problem for any long-term study in
which patients are no longer randomised or treated uniformly.
However, endpoints commonly used in MS studies (such as
relapse rate, EDSS score and time to progression of disability),
despite their intrinsic variability, become harder and more
discrete over the long term.25 26 We used a composite measure,
the ‘negative disability outcome measure’, in this study to
encompass unambiguous adverse outcomes. This was reached
when an individual had an EDSS $6.0 or had been diagnosed as
having converted to SPMS.
Statistical analysis
Statistical analyses in this study are necessarily descriptive. For
continuous data, mean, SD and median are provided. Categorical
data are described in frequency tables displaying the actual
count as well as percentages.
Baseline characteristics and clinical outcomes at LTF, including
the negative physical disability outcome, are presented for the
LTF population (table 1)21 in groups according to randomised
treatment during the pivotal study (placebo, IFNB-1b 50 mg or
Table 1 Baseline characteristics of the long-term follow-up patients as per their original treatment assignment and duration of IFNB-1b treatment
Original assignment in pivotal trial Duration of time on IFNB-1b treatment
Placebo IFNB-1b 50 mg IFNB-1b 250 mg <10% 10e79% ‡80%
Number of patients N 79 85 96 70 162 28
Gender N (% female) 56 (70.9) 59 (69.4) 64 (66.7) 50 (71.4) 111 (68.5) 18 (64.3)
Age (y) at onset of disease Mean (SD) 27.7 (6.7) 27.6 (7.9) 26.8 (5.9) 27.3 (7.2) 27.5 (6.8) 26.2 (6.5)
Median 28.0 26.0 27.0 27.0 27.0 26.5
Age (y) at start of trial Mean (SD) 35.5 (6.9) 35.6 (8.3) 35.0 (6.9) 35.7 (7.9) 35.2 (7.2) 35.2 (6.9)
Median 36.0 36.0 35.0 36.0 35.0 35.5
EDSS at baseline Mean (SD) 2.85 (1.29) 2.82 (1.35) 2.99 (1.34) 2.95 (1.28) 2.85 (1.38) 2.96 (1.09)
Median 3.00 2.50 3.00 3.00 3.00 3.00
Baseline EDSS $3.0 % 55.7 49.4 54.2 54.3 51.9 57.1
Duration of disease since onset (y) Mean (SD) 7.86 (6.28) 7.97 (6.56) 8.19 (5.72) 8.38 (6.20) 7.70 (6.25) 8.97 (5.48)
Median 6.10 5.70 7.10 6.35 6.00 7.50
MSSS at baseline Mean (SD) 4.42 (2.46) 4.20 (2.27) 4.34 (2.13) 4.25 (2.24) 4.37 (2.34) 4.20 (1.99)
Median 4.55 3.90 4.33 3.87 4.28 4.18
MRI T2 BOD (mm3) at baseline Mean (SD) 1949.85 (1969.59) 2097.78 (2457.43) 1847.14 (1590.06) 1845.97 (1896.34) 1969.90 (2102.89) 2191.69 (1853.52)
Median 1398.32 1333.10 1482.90 1404.53 1362.28 1820.00
Relapse rate in prior 2 y Mean (SD) 1.70 (0.71) 1.64 (0.71) 1.69 (0.87) 1.59 (0.61) 1.69 (0.82) 1.80 (0.82)
Median 1.50 1.50 1.50 1.50 1.50 1.50
EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score32; MRI T2 BOD, magnetic resonance imaging T2-weighted burden of disease.
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IFNB-1b 250 mg) and subgroups according to IFNB-1b exposure.
Proportions of patients reaching the negative disability outcome
(and its components) are provided together with median times
to event.
Numbers of all identiﬁed patients who died, including those
whose exact date of death was unknown, were presented by
treatment arm. Time to death from onset of disease was eval-
uated using the Kaplan-Meier method; p values from log-rank
tests for comparisons versus placebo serve descriptive purposes.
For eight patients (four from the placebo group and two in each
IFNB-1b group), missing dates of death were assumed to be the
date of LTF. Baseline characteristics and clinical outcomes are
also provided for groups according to IFNB-1b exposure.
RESULTS
Study population
All 11 original centres participated. Among original study
participants, 328/372 (88.2%) were identiﬁed. Of the patients
identiﬁed, 293/328 were alive (89.3%) and 35/328 were deceased
(10.7%). Case report forms were available for only 7 of the 35
deceased patients and these were included in the analysis. A
total of 40 identiﬁed participants declined to give consent for
follow-up. In total, case report forms were available from 260/
372 (69.9%) identiﬁed patients. A total of 260 patients had EDSS
evaluations, 192 had MRI evaluations and 179 had cognitive
assessments in English.
Baseline characteristics
The baseline characteristics of the LTF population (as originally
randomised and according to exposure to IFNB-1b) were similar
among the three study groups and were representative of the
original trial population (table 1)21. Data from patient case
report forms showed that 74/260 (28.5%) patients were taking
IFNB-1b 250 mg within 30 days of consenting to participate in
the follow-up.
Duration of treatment
After completion of the pivotal trial, patients received treat-
ments as recommended by their physician (mean 1.6 treatments
per individual, SD¼0.8). The majority (59.2%) received one MS
treatment, 25.4% received two different MS treatments, 10.4%
received three and 3.8% received four, although not necessarily
continuously, for the LTF period (ﬁgure 1).
The ranges of time on any treatment varied considerably. Of
the 260 patients studied, 40 (15.4%) received less than 6 months
of MS treatment after completion of the clinical trial, whereas
28 (10.8%) remained on IFNB-1b treatment for >80% of the
study period (>12.8 y). The majority of patients (85.8%)
received IFNB-1b 250 mg at some time during the 16 y follow-up
period. The median total length of exposure to IFNB-1b 250 mg
since the start of the pivotal trial was 7.9 y. Overall, the duration
of IFNB-1b exposure in the studied patients was 1784 patient-
years versus 623 patient-years of exposure to other DMDs or
immunosuppressive agents. There were fewer GA-treated
patients and more azathioprine-treated patients in the placebo
group than in the IFNB-1b-treated groups. In addition, there
were generally similar proportions of IFNB-1a- and IFNB-1b-
treated patients in the placebo and IFNB-1b-treated groups.
Mortality
In total, 35 deaths were recorded in the follow-up patients:
18.3% (20/109) of those identiﬁed from the original placebo
group, 8.3% (9/108) of the original IFNB-1b 50 mg group and
5.4% (6/111) of the original IFNB-1b 250 mg group. Information
on causes of death is available for nine patients and is reported
elsewhere.21 Case report forms were only available for seven of
the patients who had died. The lack of case report forms on the
remaining 28 meant that these could not be included in the
disability analyses.
The majority of deaths occurred >10 y from the start of the
pivotal study and 20 y or more after onset of ﬁrst symptoms
(ﬁgure 2). Based on estimated survival rates from the start of the
pivotal trial, patients evaluated from the 50 mg IFNB-1b and
IFNB-1b 250 mg groups had a higher likelihood of survival than
those randomised to placebo (p¼0.0402 and p¼0.0049, respec-
tively (p values uncorrected)). In the current study, based on
estimated survival rates, patients in the IFNB-1b 50 mg and
IFNB-1b 250 mg groups appeared to have a better chance of
Figure 1 Patients using IFNB-1b only
(A), disease-modifying drug (DMD) use
other than IFNB-1b stratified by original
treatment group (B) and additional DMD
use versus duration of exposure to
IFNB-1b 250 mg (C).
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survival than those randomised to placebo (p¼0.0443 and
p¼0.0029, respectively). Treatment started, on average, 8 y after
onset of MS symptoms.
Progression-related outcomes
Disability outcomes according to original randomisation showed
that a total of 113 patients reached EDSS 6.0: 45.6% (36/79) of
those originally assigned to placebo, 38.8% (33/85) of those
assigned to IFNB-1b 50 mg and 45.8% (44/96) of those assigned
to IFNB-1b 250 mg (table 2). The median times from onset of
clinical symptoms to EDSS 6.0 for the original patient treatment
groups were 14.5 y for placebo, 12.8 y for IFNB-1b 50 mg and
16.1 y for IFNB-1b 250 mg.
The pre-planned analysis of patients divided by <10% of the
time on IFNB-1b (from entry into the pivotal study until the
end of LTF duration), 10e79% of the time on IFNB-1b or $80%
of the time on IFNB-1b gave unequal divisions (n¼70, n¼162
and n¼28, respectively). Baseline characteristics are presented in
table 1. While not statistically signiﬁcant, the likelihood of
reaching EDSS 6.0 was greater for the <10% IFNB-1b group
(38.6%) and the 10e79% IFNB-1b group (46.9%) than for the
$80% IFNB-1b group (35.7%). In addition, though also statis-
tically insigniﬁcant, time from diagnosis to EDSS 6.0 was less for
the <10% IFNB-1b group (8.3 y) than for the 10e79% IFNB-1b
group (10.5 y) or for the $80% IFNB-1b group (13.6 y). Statis-
tically insigniﬁcant differences were also observed regarding
reduced incidence of SPMS (34.3% for the <10% IFNB-1b group,
44.4% for the 10e79% IFNB-1b group and 28.6% for the $80%
IFNB-1b group) and increased time from diagnosis to SPMS
(11.4 y for the <10% IFNB-1b group, 13.4 y for the 10e79%
IFNB-1b group and 13.8 y for the $80% IFNB-1b group).
Relapse rates prior to baseline, at baseline and in 2-yearly
intervals on-study or post-study showed an overall decrease in
annual relapse rate for all treatment groups from around 1.6e1.8
prior to baseline to approximately 0.3e0.6 at 15e16 y after
initiating treatment (ﬁgure 3).
Composite outcome measure
Over half (55.7%) of the patients originally assigned to placebo
reached the pre-deﬁned negative physical disability outcome
compared to 53.0% in the two combined IFNB-1b-treated groups
and with 57.3% in the IFNB-1b 250 mg group. Composite
outcomes according to treatment exposure are shown in table 3.
One patient from the IFNB-1b 50 mg group died before reaching
EDSS 6.0 or converting to SPMS, butwas reported by a ﬁrst cousin
to have died of anMS-related cause andwas, therefore, counted as
having reached a negative outcome in the statistical analyses.
DISCUSSION
Careful analysis of clinical data collected 16 y after initial
randomisation of patients to the pivotal trial of IFNB-1b was
carried out in the collected dataset. Long-term effectiveness of
IFNB-1b was difﬁcult to prove using traditional approaches,
despite the nearly 90% patient ascertainment achieved in this
study, as there was no parallel control group and assessment of
efﬁcacy is, at this stage, largely focused on the impact of the
original treatment assignments. Non-traditional approaches to
bias mitigation and data analysis will be considered in detail
elsewhere. Mortality was reduced in patients originally treated
with IFNB-1b versus placebo but the number of deceased
patients in this study was small and it is not possible to conﬁrm
a survival beneﬁt of IFNB-1b treatment. Such an effect will be
reassessed in a planned 20 y follow-up. It is of course possible
that IFNB-1B treatment could be somehow impacting on
survival independent of any therapeutic action in MS.
Relapse rates were low in the 16-y trial population compared
to baseline, but most of the patients received additional treat-
ment following completion of the short-term study. This ﬁnding
cannot be ascribed solely to use of IFNB-1b.
Table 2 Disability outcomes at 16 y for patients participating in the long-term follow-up population according to the original pivotal trial treatment
groups
Endpoint at 16 y
Original assignment in pivotal trial
Placebo IFNB-1b 50 mg IFNB-1b 250 mg
Original number of patients 123 125 124
N (proportion of original N) 79 (64%) 85 (68%) 96 (77%)
Median EDSS 5.50 5.00 6.00
Median change in EDSS 2.00 2.50 2.50
Median MSFC e0.203 e0.508 e0.468
N (%) reaching EDSS 6.0 36 (45.6) 33 (38.8) 44 (45.8)
Median time from onset of clinical symptoms to EDSS 6.0 (y)* 14.45 12.80 16.05
N (%) reaching SPMS 34 (43.0) 28 (32.9) 42 (43.8)
Median time from onset of symptoms to SPMS (y) 16.65 15.80 17.35
Patients with EDSS $6.0 or SPMS, N (%) 44 (55.7) 41 (48.2) 55 (57.3)
Median time from onset of symptoms to EDSS $6.0 or SPMS (y) 14.05 13.00 16.60
Median duration of IFNB-1b 250 mg use (y) 5.85 8.40 8.90
Median of exposure to any currently approved DMDs (y) 9.50 13.40 13.10
Note: Time was only calculated for patients who reached EDSS score of 6.0 and converted to SPMS.
*Time is calculated as the first date of EDSS score of 6.0 from the date of diagnosis of multiple sclerosis. The first date that the EDSS score was $ 6.0 is confirmed 12 months (63 months)
later to be $ 6.0.
DMDs, disease-modifying drugs; EDSS, Expanded Disability Status Scale; MSFC, Multiple Sclerosis Functional Composite Measure; SPMS, secondary progressive multiple sclerosis.
Figure 2 Death by calendar year from onset of clinical symptoms.
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A study on the efﬁcacy of GA concluded that patients who
received GA continuously over 10 y during the follow-up period
experienced better long-term outcome than patients who
withdrew from treatment (EDSS increase of 0.50 vs 2.24).20 This
16 y follow-up study of patients treated with IFNB-1b found an
apparent decrease in the incidence of reaching EDSS 6.0 or
developing SPMS compared to those who discontinued treat-
ment (>80% vs <10% exposure to IFNB-1b). However, patients
who take a treatment continuously may be more likely to do so
because of positive outcome resulting either from successful
treatment or from less aggressive disease. Similarly, patients
with poor outcome are likely to change treatments to seek
greater clinical beneﬁt. Therefore, patients continuing to receive
treatment can be self-selected for positive outcome and these
data do not necessarily imply a treatment effect.
Numerous factors confound interpretation of these data by
original treatment assignment. This analysis necessarily sacri-
ﬁces randomisation and blinding and lacks a true parallel control
group. An additional confounder is incomplete identiﬁcation and
follow-up of all patients participating in the original trial. Such
confounders have led to criticism of other long-term studies,
such as the extension trial of the PRISMS study,4 9 which
examined the beneﬁts of up to 8 y of IFNB-1a treatment. It has
been suggested that extension trials of this type support long-
term safety more than long-term efﬁcacy.27 These potential
biases impose similar difﬁculty in the interpretation of the
present efﬁcacy data as analysed by traditional methods.
However, our analyses of this 16 y follow-up have demonstrated
support for the long-term safety of IFNB-1b.
An additional complication is the widespread self-selected or
physician-selected use of other treatments, including metho-
trexate, cyclophosphamide, azathoprine, mitoxantrone, IFNB-1a
im, IFNB-1a im sc and GA. Therefore, causality cannot be
assigned to an outcome with complete conﬁdence. There did not
appear to be a bias when we examined the baseline character-
istics and performance during the pivotal study of those
participating in follow-up compared to those refusing and with
those who could not be found, but differences in the latter group
may have emerged during the ensuing years. Those patients who
did not participate in a detailed follow-up study did less well
during the randomised trial compared to those who participated
in the LTF. There was no indication that the delay in treatment
in the original placebo group versus the IFNB-1b-treated patients
had an impact on disability. The probability of reaching EDSS
6.0 did not differ among the original treatment arms. The
difference in start of any treatment between treated and placebo
arms consisted of 2e4 y by which time patients were already
into the second decade of disease. These results do not strongly
bear on the value of ‘early treatment’.
This study provided the opportunity to focus on hard
outcome measures that have face validity, such as EDSS $6.0,
SPMS and death. There was little difference for EDSS 6.0 among
the treatment arms but these data do not take into account the
28 deaths for which there were no case forms. The omission of
these data may well obscure meaningful effects of treatment
timing, because the death distribution was skewed towards an
increased mortality in the placebo arm. If the deaths could be
shown to be related to incremental disability, this would be
more favourable to the treatment arms. The endpoints
commonly used in short-term clinical trials, such as relapse rate
and MRI outcomes, are indirect measures that, prior to this
study, had an uncertain association with these long-term ‘hard’
outcomes or even shorter-term ones.28 The difference in
mortality between the original patient groups is a novel obser-
vation that will be further explored.
The results here represent the longest available follow-up of
any DMD and may also be the most complete and compre-
hensive. The ﬁnal evaluation after 16 y from study entry
comprises more than 4000 patient-years. This actually extends
beyond two decades from disease onset on average, because, at
study entry, mean duration of disease from clinical presentation
was 8.02 y (SD¼6.15). Other follow-up studies of DMD treat-
ment have encountered similar difﬁculties with patient identi-
ﬁcation but have had shorter periods of observation.4 15e20 The
duration of these trials may have been too short to identify
a clear mortality beneﬁt of treatment, which even this study can
only propose. Life expectancy for patients with MS has been
estimated to be between 5 and 10 years less than for individuals
without the disease.29 30 In the Danish Multiple Sclerosis
Registry, MS or complications of the disease accounted for more
than half of the deaths that occurred.31 Whether or not DMD
treatment can reduce the raised mortality risk for patients
with MS is an important question and warrants further
investigation.
Long-term data on the clinical outcomes of MS treatment are
potentially of great importance to physicians, patients and
third-party payers. However, conclusive evidence could not be
gained using the methodologies used in short-term randomised
clinical trials. Further exploration of methods for the interpre-
tation and analysis of non-randomised long-term data is needed.
Author footnote
16 y long-term follow-up study investigators: University of Chicago, Illinois, USA: B
Arnason (Principal Investigator (PI)), A Reder, A Javed, A Noronha (Investigators (I]), B
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*Only calculated for patients who reached these endpoints.
EDSS, Expanded Disability Status Scale; SPMS, secondary progressive multiple sclerosis.
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